← Back to Clinical Trials
Recruiting NCT05615610

NCT05615610 Effects of Transcutaneous Electrical Nerve Stimulation on Cognitive Function and Upper Limb Motor Function in People With Chronic Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05615610
Status Recruiting
Phase
Sponsor The Hong Kong Polytechnic University
Condition Chronic Stroke
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2023-11-01
Primary Completion 2025-12-15

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
tSCStVNSControl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2023-11-01 with a primary completion date of 2025-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Upper limb impairment is present in more than 85% of people with stroke, which greatly affect the quality of life, social participation, and performance of daily activities of people with stroke. Previous study also revealed that 53.4% of people after stroke experienced cognitive impairment. Different cognitive domains might be affected following stroke, such as attention, memory, language, and orientation, and the problems with memory are often prominent. Yet, there is no effective treatment for the post-stroke cognitive impairment. Transcutaneous spinal cord stimulation (tSCS) and transcutaneous vagus nerve stimulation (tVNS) are simple and non-invasive treatment to improve upper limb motor function and cognitive function. However, no existing studies have explored on the effects of tSCS and tVNS on cognitive function in people with stroke. Therefore, the purpose of this study is to evaluate the effectiveness of transcutaneous electrical nerve stimulation (TENS) on improving upper limb function and cognitive function in people with chronic stroke.

Eligibility Criteria

Inclusion Criteria: 1. aged between 50 and 80; 2. have suffered from a single stroke at least 6 months; 3. had volitional control of the non-paretic arm and at least minimal antigravity movement in the paretic shoulder; Exclusion Criteria: 1. have cardiac pacemaker or cochlear implant; 2. have other neurological diseases; 3. are taking medication that may affect measured outcomes; 4. have skin lesions, infection, or inflammation near selected position; 5. are participating in other drug/treatment programs.

Contact & Investigator

Central Contact

Shamay NG, PhD

✉ shamay.ng@polyu.edu.hk

📞 +852 27664889

Principal Investigator

Shamay NG, PhD

PRINCIPAL INVESTIGATOR

The Hong Kong Polytechnic University

Frequently Asked Questions

Who can join the NCT05615610 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Chronic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05615610 currently recruiting?

Yes, NCT05615610 is actively recruiting participants. Contact the research team at shamay.ng@polyu.edu.hk for enrollment information.

Where is the NCT05615610 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT05615610 clinical trial?

NCT05615610 is sponsored by The Hong Kong Polytechnic University. The principal investigator is Shamay NG, PhD at The Hong Kong Polytechnic University. The trial plans to enroll 90 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology